Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
27 mai 2022 11h30 HE
|
Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...
Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's Disease
27 avr. 2022 08h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights
28 mars 2022 16h05 HE
|
Acumen Pharmaceuticals, Inc.
Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical testing Currently enrolling INTERCEPT-AD, a...
Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
16 mars 2022 16h15 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting
24 févr. 2022 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
04 janv. 2022 01h15 HE
|
Novartis Pharma AG
Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosing...
Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights
15 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical...
Global Neurological Therapies Market Research Report 2021: Competitive Landscape and Pipeline Analysis Focusing Specifically on Therapeutic Interventions for Neurodegenerative Diseases
15 nov. 2021 07h08 HE
|
Research and Markets
Dublin, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The "Global Neurological Therapies Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This research has identified novel...
Acumen Pharmaceuticals to Present at Upcoming Investor Conferences
08 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
02 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first...